Cancer Archives

News and Trends 4 Nov 2015

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets in Immuno-onology is a top-shelf cancer R&D area, with Germany’s CureVac also attracting another €100M yesterday for their mRNA platform (which targets lung and prostate […]

November 4, 2015 - 3 minutesmins - By Dani Bancroft

peter Llewellyn Davies medigene interview

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

This is the third interview we publish from BIO (yes, we are working hard). It comes after the interview of Simon Moroney, CEO of MorphoSys and Jane Dancer, CBO of F-star. Medigene is another big/famous Biotech company of Munich, Germany. It was founded over 20 years ago and is now specialised in cell-based therapies. It counts […]

November 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 3 Nov 2015

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

“The RNA People” at CureVac in Tübingen (Germany) have a new €100M investment into their RNA platform, which has prophylactic purposes for common viruses, pipeline candidates for prostate cancer, lung cancer and research into vaccines for HIV, Tuborculosis and Rabies. Indeed, the financial success surrounding their mRNA work has been startlingly impressive, with the EU […]

November 3, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 3 Nov 2015

Exclusive from BIO-Europe 2015: Interview with F-star, a Cambridge-UK Immuno-oncology Biotech

Second interview of BIO-Europe 2015. This time, it’s a British company from Cambridge (UK): F-star. This morning we spoke with their CBO Jane Dancer. F-star is developing bi-specific antibodies for immuno-oncology and inflammatory disease. It has raised a total of 38 million euros from top EU VCs. Jane Dancer’s business tenure within the field is […]

November 3, 2015 - 1 minutemin - By Philip Hemme

News and Trends 30 Oct 2015

Purple GMO Tomatoes are Growing Medicines in the UK

Meet the purple tomatoes which produce as much Revervesterol in a single fruit as 50 bottles of wine, and as much anti-breast cancer chemical as 2.5Kg of Tofu! The John Innes Centre in Norwich (East England) have engineered these tomato plants to produce larger amounts of these health-related compounds. With funding from the Biotechnology and […]

October 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Oct 2015

Cellectis UCART Milestone: One step closer to a Universal CAR-T Therapy for Blood Cancer

Cellectis is a leader in immuno-oncology CAR-T therapies from France, which might revolutionise cancer treatments. Now, the next step in the CAR-T campaign is to step away from personalised (autologous) therapies, which are time-consuming and expensive, to instead produce an allogenic version available to all. So, what is CAR-T? You can read a more in-depth […]

October 29, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 29 Oct 2015

ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells

ERRATUM: I published a first article on Celyad’s new patent on last Tuesday where I made an error of judgement. Celyad’s US patent covers allogeneic CAR-T modified to reduce immunogenicity. In my previous article, I wrote that Celyad stated having obtained the first US patent on CAR-T, which is wrong. Last Tuesday, Celyad announced having […]

October 29, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 26 Oct 2015

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

Amgen is now months away from a European approval with Imlygic (also known as T-VEC) – the first oncolytic immunotherapy for advanced melanoma. The Committee for Medicinal Products for Human Use (CHMP) and the scientific committee of the European Medicines Agency (EMA), have reacted positively. Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, […]

October 26, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 23 Oct 2015

#Sorry: The World-leading Oncology Company fails in Phase III

Antibody Drug Conjugate is a smart way to improve chemotherapy. That is the strategy of Roche / Immunogen‘s drug Kadcyla®, which has just failed in Phase III clinical trial to extend its indications. Here are the facts… Antibody Drug Conjugate is at the boundary between chemical and biological drug. The principle is pretty simple; once the antibody fixes to […]

October 23, 2015 - 2 minutesmins - By Jerome Topsent

News and Trends 23 Oct 2015

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Novartis, the Swiss Biotech giant, has once again broadened its Immuno-oncology portfolio with the acquisition of US Admune Therapeutics (MA) and forming marketing, commercialization and development partnerships with California’s Xoma and Palobiopharma in Barcelona (Spain). Novartis is a Basel giant in the biotech industry, with their research development programs spanning a broad range of fields […]

October 23, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 23 Oct 2015

Biotech of the week: Genenta Biosciences, a Novel Gene Therapies from Italy

This week we depart from East Germany and head south, through both Liechtenstein and Switzerland to the northern region of Italy, Lombardy. Here we arrive in Italy’s second largest city, Milan. This city is the center of fashion, Italian cuisine and is home to Da Vinci’s, ‘The Last Supper’ however, it is also home […]

October 23, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 22 Oct 2015

This €200M French Biotech uses Red blood Cells to Fight Leukemia & Pancreatic Cancer

Lyon’s Erytech (France) is a clinical biopharma working on improving its red blood cell transported drug, targeting cancers such as acute lymphocytic leukemia (ALL) and pancreatic adenocarcinoma. Now phase I/II trials for its GRASPA therapy have demonstrated good efficacy and safety. Circulating asparagine is needed by cancer cells to grow and proliferate. Erytech’s platform uses […]

October 22, 2015 - 2 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Exclusive from BIO-Europe 2015: Interview of Peter Llewellyn-Davies, CFO at Medigene, Munich-based Immunotherapy Biotech

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

Exclusive from BIO-Europe 2015: Interview with F-star, a Cambridge-UK Immuno-oncology Biotech

Purple GMO Tomatoes are Growing Medicines in the UK

Cellectis UCART Milestone: One step closer to a Universal CAR-T Therapy for Blood Cancer

ERRATUM: Celyad’s US patent on TCR-deficient allogeneic CAR-T cells

The First Ever Oncolytic Immunotherapy is Set to Reach the European Market

#Sorry: The World-leading Oncology Company fails in Phase III

Novartis Monopolises Immuno-Oncology: Three More Biotechs taken Under its Wing

Biotech of the week: Genenta Biosciences, a Novel Gene Therapies from Italy

This €200M French Biotech uses Red blood Cells to Fight Leukemia & Pancreatic Cancer

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!